# AMPLIFY-7P

Source: https://onco.cc/trials/amplify-7p/  
OnCo record `amplify-7p` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The randomised test of an off-the-shelf KRAS vaccine after pancreatic surgery. It missed its primary goal in June 2026.

## Summary

Did not meet the pre-specified primary DFS endpoint in the intent-to-treat population; post-hoc landmark analyses suggested ~14% absolute DFS benefit during active dosing. Company is exploring R0-resected subgroups for phase 3. A cautionary data point for shared-antigen vaccines versus personalised approaches.

## Fields

- Kind: Trial
- Status: negative
- Last checked: 2026-09-06
- Registry id: NCT05726864
- Phase: 1/2
- Setting: Adjuvant mKRAS PDAC after surgery and chemotherapy: ELI-002 7P vs observation
- Sponsor: Elicio Therapeutics
- Enrolled: 158
- Result: Primary DFS endpoint not met.
- Outcomes: Disease-free survival (ITT): ELI-002 7P vs Observation; Disease-free survival at 3 months (landmark): ELI-002 7P 90.3% vs Observation 76.6%; Disease-free survival, R0-resected subgroup (post hoc): ELI-002 7P 23.8 months vs Observation 12.8 months, HR 0.65
- Replication: Randomised phase 2 missed its primary ITT endpoint (June 2026); the post hoc R0 subgroup signal is unreplicated and the sponsor plans a refined phase 3.

## Sources

- ClinicalTrials.gov NCT05726864: https://clinicaltrials.gov/study/NCT05726864

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/)
- drugs: [ELI-002 7P](https://onco.cc/drugs/eli-002-7p/)
- companies: [Elicio Therapeutics](https://onco.cc/companies/elicio-therapeutics/)
- terms: [Pancreatic cancer: the failed and stopped programmes and why](https://onco.cc/terms/pancreatic-failed-programmes/)
- trials: [A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC](https://onco.cc/trials/nct05968326/), [Autogene cevumeran phase 1 in resected pancreatic cancer (Memorial Sloan Kettering)](https://onco.cc/trials/autogene-cevumeran-phase-1/), [ECLIPSE (GVAX pancreas and CRS-207)](https://onco.cc/trials/eclipse/)
- roadmaps: [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/)
- bottlenecks: [The undruggable drivers](https://onco.cc/bottlenecks/b-undruggable-targets/)

---
JSON: https://onco.cc/api/v1/entities/amplify-7p.json